PMID: 2113398May 1, 1990Paper

Typing of polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
B OjeniyiN Høiby

Abstract

The study assesses the reproducibility, typability and discriminatory power of several typing methods for Pseudomonas aeruginosa isolated from cystic fibrosis patients. 178 polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients were serotyped using polyclonal sera and monoclonal antibodies, phage typed, pyocin typed and reverse phage typed. 31 of these polyagglutinable isolates, six monoagglutinable isolates and three nontypable isolates were also typed by means of hybridization using a DNA probe. In a comparison of the methods used, on polyagglutinable isolates only, typability was 0% with polyclonal sera, 90% with monoclonal sera, 94% with phage typing, 85% with pyocin typing, 36% with reverse phage typing and 100% with DNA-prope typing. Using monoclonal antibodies, the reproducibility was 75%, while that of phage typing was 88%, pyocin typing 53% and reverse phage typing 62%. Typing with the DNA probe was not repeated. using polyclonal sera, repeated typing showed that 94% of the isolates were polyagglutinable. Using phage typing, 40% of the isolates belonged to phage type 31, while 60% were distributed amongst 32 phage types. Using monoclonal antibodies, 71% of the isolates belonged to 0-group 3, and...Continue Reading

References

Apr 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T L Pitt
Jul 1, 1989·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·B OjeniyiV T Rosdahl
May 1, 1989·Acta paediatrica Scandinavica·N Høiby, S S Pedersen
Jan 1, 1987·The Journal of Infectious Diseases·J W OgleM L Vasil
Apr 1, 1988·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·B Ojeniyi
Feb 1, 1969·Journal of Medical Microbiology·J R Govan, R R Gillies

❮ Previous
Next ❯

Citations

Jun 1, 1991·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·B OjeniyiV T Rosdahl
Feb 1, 1993·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·B OjeniyiN Høiby
Apr 9, 2008·Médecine et maladies infectieuses·A Hafiane, M Ravaoarinoro
Apr 16, 2011·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Baoleri LeeOana Ciofu
Jul 1, 1993·The Journal of Hospital Infection·C L Poh, C C Yeo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.

© 2021 Meta ULC. All rights reserved